Back to Search
DANIJELA JELOVAC, MD
MD
Medical Oncology Physician
NPI: 1053593582IndividualAccepts Medicare
Education
OTHER
Class of 1999
Research & Publications (18)
Inhibition of the phosphatidylinositol 3-kinase/Akt pathway improves response of long-term estrogen-deprived breast cancer xenografts to antiestrogens.
PMID 17473209·Clin Cancer Res·2007
7-preclinical
Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice.
PMID 16397039·Clin Cancer Res·2006
4-observational
The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells.
PMID 15994225·Proc Natl Acad Sci U S A·2005
4-observational
Model systems: mechanisms involved in the loss of sensitivity to letrozole.
PMID 15967659·J Steroid Biochem Mol Biol·2005
7-preclinical
Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
PMID 15958593·Cancer Res·2005
4-observational
Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole.
PMID 15958587·Cancer Res·2005
7-preclinical
The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation.
PMID 15867390·Cancer Res·2005
8-other
Potent CYP17 inhibitors: improved syntheses, pharmacokinetics and anti-tumor activity in the LNCaP human prostate cancer model.
PMID 15555909·J Steroid Biochem Mol Biol·2004
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 8613 ROUTE 29 STE 200
FAIRFAX, VA 22031 - Phone
- (571) 350-8400
Quick Facts
- NPI
- 1053593582
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 27
- Publications
- 18
Are you this provider?
Claim Your Profile